Roche and Novo-backed small molecule therapy developer Aligos Therapeutics has floated in an initial public offering priced in the middle of its range.

US-headquartered small molecule drug developer Aligos Therapeutics went public on Friday in a $150m initial public offering representing an exit for pharmaceutical firms Roche and Novo. The company priced 10 million shares in the middle of the IPO’s $14 to $16 range. Its shares opened at $17.40 on the Nasdaq Global Select Market and closed…

The rest of this content is only accessible to Global Corporate Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.